Skip to main content
Download PDF

Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Trials volume 24, Article number: 487 (2023) Cite this article

The Original Article was published on 15 February 2023

Correction: BMC Trials 24, 112 (2023)

https://doi.org/10.1186/s13063-023-07087-5

Following publication of the original article [1], we have been notified that affiliations 1 to 4 are actually different titles within the same department and should be gathered under just one affiliation.

Additionally, the following sentence was added in the Funding section: This study was supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-227).

The original article has been corrected.

Reference

  1. Bai, et al. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients. BMC Trials. 2023;24:112. https://doi.org/10.1186/s13063-023-07087-5.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Wei Bai and Fan Yang contributed equally to this study.

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China

    Wei Bai, Fan Yang, Xiaofeng Zeng & Xiaomei Leng

  2. Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China

    Huji Xu

  3. Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China

    Wei Wei

  4. Department of Rheumatology, The Afliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China

    Hongbin Li

  5. Department of Rheumatology, Third Hospital of Shanxi Medical University, Bethune Hospital Shanxi Academy of Medical Sciences, Taiyuan, Shanxi, China

    Liyun Zhang

  6. Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University, Beijing, China

    Yi Zhao

  7. Department of Rheumatology and Immunology, The First Afliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China

    Xiaofei Shi

  8. Department of Rheumatology and Immunology, Tangdu Hospital, Fourth Military Medical University (Air Force Medical University), Xi’an, Shaanxi, China

    Yan Zhang

Authors
  1. Wei Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huji Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongbin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liyun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaofei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiaofeng Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiaomei Leng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaofeng Zeng or Xiaomei Leng.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bai, W., Yang, F., Xu, H. et al. Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients. Trials 24, 487 (2023). https://doi.org/10.1186/s13063-023-07546-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13063-023-07546-z

Trials

ISSN: 1745-6215